he identification of individual or clusters of predictive genetic alterations might help in defining the outcome of cancer treatment, allowing for the stratification of patients into distinct cohorts for selective therapeutic protocols. Neuroblastoma (NB) is the most common extracranial childhood tumour, clinically defined in five distinct stages (1–4 & 4S), where stages 3–4 define chemotherapy-resistant, highly aggressive disease phases. NB is a model for geneticists and molecular biologists to classify genetic abnormalities and identify causative disease genes. Despite highly intensive basic research, improvements on clinical outcome have been predominantly observed for less aggressive cancers, that is stages 1,2 and 4S. Therefore, stages 3–4 NB are still complicated at the therapeutic level and require more intense fundamental research. Using neuroblastoma as a model system, here we herein outline how cancer prediction studies can help at steering preclinical and clinical research toward the identification and exploitation of specific genetic landscape. This might result in maximising the therapeutic success and minimizing harmful effects in cancer patients.

Amelio, I., Bertolo, R., Bove, P., Candi, E., Chiocchi, M., Cipriani, C., et al. (2020). Cancer predictive studies. BIOLOGY DIRECT, 15(1), 18.

Cancer predictive studies

Amelio, Ivano;Bove, Pierluigi;Candi, Eleonora;Chiocchi, Marcello;Cipriani, Chiara;Di Daniele, Nicola;Mauriello, Alessandro;Palmieri, Giampiero;Piacentini, Mauro;Sica, Giuseppe;Tesauro, Manfredi;Rovella, Valentina;Tisone, Giuseppe;
2020

Abstract

he identification of individual or clusters of predictive genetic alterations might help in defining the outcome of cancer treatment, allowing for the stratification of patients into distinct cohorts for selective therapeutic protocols. Neuroblastoma (NB) is the most common extracranial childhood tumour, clinically defined in five distinct stages (1–4 & 4S), where stages 3–4 define chemotherapy-resistant, highly aggressive disease phases. NB is a model for geneticists and molecular biologists to classify genetic abnormalities and identify causative disease genes. Despite highly intensive basic research, improvements on clinical outcome have been predominantly observed for less aggressive cancers, that is stages 1,2 and 4S. Therefore, stages 3–4 NB are still complicated at the therapeutic level and require more intense fundamental research. Using neuroblastoma as a model system, here we herein outline how cancer prediction studies can help at steering preclinical and clinical research toward the identification and exploitation of specific genetic landscape. This might result in maximising the therapeutic success and minimizing harmful effects in cancer patients.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/18
English
Con Impact Factor ISI
Amelio, I., Bertolo, R., Bove, P., Candi, E., Chiocchi, M., Cipriani, C., et al. (2020). Cancer predictive studies. BIOLOGY DIRECT, 15(1), 18.
Amelio, I; Bertolo, R; Bove, P; Candi, E; Chiocchi, M; Cipriani, C; Di Daniele, N; Ganini, C; Juhl, H; Mauriello, A; Marani, C; Marshall, J; Montanaro, M; Palmieri, G; Piacentini, M; Sica, G; Tesauro, M; Rovella, V; Tisone, G; Shi, Y; Wang, Y; Melino, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
13062_2020_Article_280.pdf

accesso aperto

Licenza: Non specificato
Dimensione 836.48 kB
Formato Adobe PDF
836.48 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/303242
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact